B
artter syndrome is an autosomal recessive kidney disorder characterized by hypokalemia, metabolic alkalosis, and normal blood pressure (1 (11) (12) (13) (14) . Clinical signs of Gitelman syndrome include hypokalemic alkalosis with normal blood pressure, hypomagnesemia, and hypocalciuria. The hypercalciuria in Gitelman syndrome is influenced by defective thiazidefinely tuned transport system in the convoluted tubules (15, 16) .
Early diagnosis and appropriate treatment of fluidelectrolyte disorders in infants and young children may improve growth and prevent or retard the disease progression to kidney failure.
The standard therapy includes KCL supplementation, prostaglandin E inhibitors (NSAIDS), angiotensinconverting enzyme inhibitors (ACEI) such as enalapril, and aldosterone antagonists such (spironolactone or amiloride) (17) (18) (19) (20) (21) .
However, hypokalemic alkalosis persists in majority of patients despite of combination therapy with K + sparing diuretics, angiotensin-converting enzyme inhibitors (ACEI), and nonsteroidal anti-inflammatory drugs (NSAIDs). Acetazolamide, a carbonic anhydrase inhibitor, has been used frequently and effectively for the management of hypokalemic alkalosis as a result of loop diuretics administration, especially in critically ill patients with congestive heart failure (22) (23) (24) (25) .
There is no information available on the efficacy of acetazolamide on the management of severe hypokalemic alkalosis refractory to the standard therapy. A benefit from acetazolamide appears to be apparent in the management of hypokalemic alkalosis in patients with Barter syndrome. Acetazolamide, prevents reabsorption of sodium bicarbonate in the proximal tubule, thereby causing bicarbonate wastage (26) .
The low cost, limited side effects and the ease of administration are compelling evidence to consider acetazolamide for the treatment of hypokalemic alkalosis in patients with Batter syndrome unresponsive to the conventional therapy.
Author's contribution
FA is the single author of the paper.
Conflicts of interest
The author declare no conflict of interest.
Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the author.
Funding/Support
None.
